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 Research has continued to provide conflicting results of caffeine’s effect on acute 
coronary events; although it is now apparent that a single nucleotide polymorphism at 
intron 1 of the cytochrome P450 (CYP1A2) gene may explain these equivocal findings.  
Despite the fact that markers of coagulation potential and fibrinolytic potential are 
associated with risk for myocardial infarction, the extent to which caffeine affects these 
markers is unknown.  The purposes of this study were to determine the acute effects of 
caffeine on coagulation and fibrinolytic potential at rest and following maximal exercise 
and to determine if hemostatic responses engendered by caffeine are influenced by the 
aforementioned CYP1A2 polymorphism.  20 healthy, recreationally active, males (age, 
21.4± 1.2 SD; weight, 81.9 ± 10.4 SD; 180.6 ± 7.1 SD; VO2peak 46.4 ± 6.17 SD 
mL∙kg∙min
-1
) participated in this study.  Subjects performed two graded maximal exercise 
tests (GXT’s) after consuming either 6 mg/kg of caffeine or placebo 1 hour before trials. 
DNA was obtained from whole blood samples and genotyping was done using restriction 
fragment length polymerase chain reaction. Subjects were categorized as possessing the 
C allele (C allele carriers) or being homozygous for the A allele (AA homozygotes).  The 
effects of treatment (caffeine, placebo), time (pre-exercise, post-exercise), and treatment 
x genotype were assessed using Repeated Measures Analysis of Variance (RMANOVA).  
Caffeine was shown to increase plasma Factor VIII levels when compared to placebo, but 
this was no longer significant when covarying for the increased exercise time engendered 
by caffeine.  Fibrinogen values significantly increased post-exercise (p < 0.05) for C 
allele carriers but not for AA homozygotes.  Finally, caffeine caused a significantly 





suggest that caffeine may increase Factor VIII response to graded exercise (GXT) 
secondary to an effect on time to fatigue (TTF).  Caffeine also appears to increase 
fibrinolytic potential at rest and after exercise.  Additionally, the aforementioned 







There has been conflicting research related to caffeine’s effect on cardiovascular 
disease, serum lipids, and acute coronary events [6,12,16,29,33,34,,44,45,48, 53].  
Current literature shows both J and U-shaped relationships between cardiovascular 
disease risk and coffee consumption, suggesting a type of protective effect for moderate, 
but not light or heavy drinkers [29,36,48].  Furthermore, numerous studies evaluating the 
consumption of caffeinated versus decaffeinated coffee show preventative cardiovascular 
benefits [13,34,41] while others show an increased relative risk for acute coronary events 
like myocardial infarction and stroke [29,48,53].  It has also been suggested that coffee 
consumption may acutely trigger a myocardial infarct in sedentary individuals that drink 
less than 2 cups of coffee per day or those whom do not consume coffee daily [6].  
Happonen et al observed a dose-dependent relationship for risk of acute myocardial 
infarction [6], while Kim et al found that daily consumption of 4 or more cups of coffee 
per day may elicit a protective effect for stroke [53]. 
The association of cardiovascular disease with coffee consumption has been 
investigated for several decades, yet findings have obviously been equivocal.  As an 
example, a prior meta-analysis included findings from 22 cohort and case-control studies 
from 1968 to 1992.  Half of the cohort studies observed a relative risk ratio of 1.3-1.5 for 
acute myocardial infarction with the consumption of at least 5 cups of coffee per day; 
while the other half showed no increased risk of such events [25].  Similarly, an analysis 




additional risk of CHD whereas the case-control studies resulted in a 60% increase in risk 
in those who consume 5 cups of coffee per day or more [34].  However, after further 
investigation, it has been noted that a majority of these analyses did not control for other 
variables that may influence the relative risk of cardiovascular disease such as smoking 
status, habitual alcohol consumption, and dietary factors [12,25,33,34].  Because of this, 
Sofi and colleagues controlled for multiple variables including age, gender, smoking 
status, history of MI, and, physical activity [54]. The meta-analysis showed a risk ratio of 
1.83 in drinkers that consumed more than 4 cups of coffee per day for Coronary Heart 
Disease in the case-control studies analyzed. In contrast, the long-term follow-up cohort 
studies showed no additional risk of CHD with any level of coffee consumption [54]. 
A more recent study evaluated the results of the Nurses’ Health Study and Health 
Professionals Follow-Up Study which included bi-annual reports of coffee consumption 
and health outcomes of more than 120,000 male and female participants over a period of 
34 years.  After correcting for smoking status, a significant inverse association was found 
between coffee consumption and all-cause deaths, suggesting a positive health benefit 
from coffee consumption [41].  In addition, among women, 5 to 7 cups of coffee per day 
resulted in a 7% reduced risk of death compared to non-drinkers.  Furthermore, a 
reduction in all-cause death was observed across levels of coffee consumption, with a 
reported 18% reduction in those drinking 2-3 cups per day, 26% drinking 4-5 cups per 
day, and 17% drinking 6+ cups per day.  These findings support the notion that coffee 
consumption in women may exhibit a protective effect in moderate drinkers [48].  
Additionally, the National Institute of Health – AARP Diet and Healthy Study evaluated 




smoking, an inverse association was observed between every level of coffee consumption 
and specific-cause mortality rate related to heart disease, stroke, respiratory disease, and 
diabetes. [23]. 
In contrast, a recent study by Liu and colleagues analyzed deaths during a 17 year 
period in 43,727 participants from the Aerobics Center Longitudinal Study. A 
multivariate analysis showed a positive association between coffee intake and all-cause 
mortality in men [40].  When adjusted for age, a significant association between high 
coffee consumption and all-cause mortality was observed for both men and women 
younger than 55.  In addition, a positive relationship between coffee and blood lipids was 
observed by Cai et al.  The group analyzed 12 randomized controlled trials performed 
that included coffee drinking as the active treatment intervention.  All 12 studies 
monitored total cholesterol, LDL, HDL, and TGs over a period of at least 45 days [12].  
LDL and triglyceride levels increased and this effect was more pronounced in those who 
were previously diagnosed for hyperlipidemia [12,32].  Studies investigating the effect of 
coffee on serum lipids have yielded similar results in addition to an observed increase in 
inflammatory markers [18,55]. 
 While the literature in regards to coffee consumption and cardiovascular risk 
remains ambiguous at best, the effect of caffeine on hemodynamic response is 
unequivocal.  Caffeine has been known to increase heart rate, blood pressure, myocardial 
contractility, and cardiac output [7,12,13,2933,34,44,45,49]. Prior data shows that 
contractility significantly increases 90 minutes after ingestion, and does not return to 
baseline until 4.5 hours after the initial dosage [7].  Caffeine’s effect on heart rate is a 




of other stimulants [12,19,29,33,34,44,45].  Caffeine also increases blood pressure by 
inhibition of adenosine receptors as well as increased neuroendocrine stimulation 
[12,29,33,34,43-45].  A study on a group of healthy, non-coffee drinkers showed 
significant increases in blood pressure and total peripheral resistance following ingestion 
of 200 milligrams of caffeine [13]. Additionally, Papaioannou observed acute increases 
in arterial stiffness after the ingestion of caffeine [49].  These effects can be seen within 
30 minutes of consumption and continue for 4 or more hours [43].  While increases in 
systolic pressure range between 3 and 15 mmHg, diastolic pressures can also rise 4-13 
mmHg [43]. Habitual coffee consumption has been theorized to influence the effect of 
caffeine on the neuroendocrine and cardiovascular system.  However, it has been found 
that tolerance minimally attenuates the corresponding responses in blood pressure, heart 
rate, and total peripheral resistance following caffeine consumption [22,52,57].  These 
acute physiological effects could be especially important in those at risk for 
cardiovascular disease. 
Although hemodynamic responses to caffeine may lead to acute myocardial 
infarction, it is understood that a majority of myocardial infarctions result from an 
occlusive thrombus [24,37,53].  Unstable plaques rupture, resulting in thrombus 
formation that can completely occlude coronary arteries. Thus, plasma markers of 
coagulation potential and clot lysis (fibrinolysis) are clinically important [50,59].  
Markers of coagulation potential include factors that make up the coagulation cascade 
and fibrinogen, the inactive precursor to fibrin.  In humans, fibrinolysis is regulated by 
conversion of plasminogen in to plasmin which degrades fibrin to smaller fibrin dimer 




The main circulating inhibitor of tPA is plasminogen activator inhibitor (PAI-1), which 
binds to tPA and forms an inactive complex.  The hemostatic response to exercise is of 
particular clinical significance as 80% of exertion-related ischemic events occur due to an 
occlusive thrombus [24].  Exercise acutely increases coagulation potential [20,21], which 
is offset by a corresponding increase in fibrinolytic activity [59]. 
Coffee and caffeine consumption was originally linked to myocardial infarction 
based on its potential to induce arrhythmias, although this theory has long been 
discredited [19,25].  However, it is possible that acute [30] and chronic [18] caffeine 
intake has a role in increasing coagulation potential.  In a recent study, participants were 
exposed to a series of cognitive tasks, including a speech challenge and timed arithmetic 
tasks, specifically designed to elicit stress.   After the ingestion of a placebo drink or 3.3 
mg/kg of caffeine, higher levels of fibrinogen were observed following caffeine ingestion 
at rest, 15 minutes after exposure to the stressor, and during the recovery period [30].   In 
contrast, Bak et al observed that nine weeks of caffeine supplementation did not alter 
markers of coagulation. In this study, 107 young, healthy adults were given 75 mg of 
caffeine or placebo per day for a period of 9 weeks.  There were no observed effects of 
caffeine consumption on resting levels of factor VII, factor VIII, and fibrinogen [4].  
Thus, whether or not caffeine affects hemostasis is not fully known and the interaction 
between caffeine intake and exercise on the hemostatic profile has not been evaluated. 
The equivocal findings on the relationship between coffee intake and risk of MI, 
and the conflicting findings regarding caffeine's effect on hemostasis could be explained 
by genetic differences.  Cytochrome P450 (CYP1A2) is a hepatic enzyme that is 




nucleotide (A/C) polymorphism at intron 1 of the CYP1A2 gene influenced the degree to 
which coffee consumption was associated with risk of myocardial infarction [17].  Coffee 
consumption increased MI risk in study participants that possessed a C allele, but was not 
linked to MI risk in individuals homozygous for the A allele.  Prior research has shown 
that C allele carriers have slower caffeine metabolism than AA homozygotes [16], 
suggesting that the increased MI risk in C-allele carriers was due to higher plasma 
caffeine levels following caffeine dosage.  This polymorphism has also been shown to 
influence the association between caffeine and bone mineral density [27] and the 
ergogenic response to caffeine in cyclists [60].  The former study evaluated whether the 
CYP1A2 polymorphism impacted the long-term effect of drinking high amounts of 
coffee and corresponding bone mass in an elderly population.  Bone mineral density was 
evaluated for coffee drinkers who consumed greater than 4 cups of coffee per day and 
was lower in AA homozygotes genotype than in C allele carriers.  It was hypothesized 
that the lower BMD may be due to caffeine’s potential to increase calcium excretion and 
decrease absorption that can lead to lower bone mineral density.  Furthermore, the lower 
BMD in AA homozygote may have been due to the impact of caffeine metabolites on the 
aforementioned effects of caffeine on BMD [27].  Womack et al observed that caffeine 
significantly improved cycling time trial performance in AA homozygotes to a greater 
degree than in C allele carriers [60].  While the mechanisms for these effects are still 
unknown, the implications of such findings suggest that this genetic polymorphism exerts 
a very powerful influence on caffeine response. 
If caffeine increases risk of MI due to alterations in hemostasis, it could be 




of caffeine on the coagulation and/or fibrinolytic profile.  The purposes of the present 
study are to:  1) determine the acute effects of caffeine on coagulation and fibrinolytic 
potential at rest and following maximal exercise and 2) determine if hemostatic responses 
engendered by caffeine are influenced by the aforementioned CYP1A2 polymorphism.  It 
is hypothesized that caffeine will increase coagulation potential both at rest and after 
exercise and this increase will be more pronounced in C-allele carriers. 
 
Assumptions 




- No Females used in study 
- All healthy subjects without previous clinical complications (CVD, Chronic 
Illness) 
- All “young” healthy males 
 
Delimitations 





- All subjects were non-smokers 
- All subjects were fasted of food at least 10 hours before each trial 
- All subjects had no illnesses or infections at the time of testing 
Definition of Terms  
Markers of Coagulation:  
a. Factor VIII 
b. Fibrinogen 
Markers of Fibrinolysis: 
a. Tissue-Plasminogen Activator (tPA) 
b. Tissue-Plasminogen Activator Antigen (tPA Antigen) 













  A total of 20 healthy, recreationally active, males (age, 21.4 ± 1.2; weight, 81.9 ± 
10.4; 180.6 ± 7.1; VO2peak 46.4 ± 6.17 mL∙kg∙min
-1
) participated in this study.  All 
subjects were non-smokers, recruited from a university setting without any reported 
chronic illness or condition.  Written informed consent was obtained from all participants 
prior to participation.  The study and consent form were approved by the James Madison 
University Institutional Review Board. 
 
Experimental Protocol 
The study used a randomized, double-blind, crossover design.  All subjects 
performed a 10 hour fast on the night before each trial and refrained from the 
consumption of caffeine and alcohol for 24 hours prior to each trial.  Exclusion criteria 
included any illness 7 days prior to the trial as well as the use of medication within 24 
hours of any trial.  Subjects performed two graded maximal exercise tests (GXT’s).  All 
trials were performed before 10:00 hours in order to minimize the possibility of diurnal 
variation in fibrinolysis [2].  Subjects ingested 6 mg/kg of pharmaceutical grade caffeine 
(Nutrabio, New Jersey) or placebo 1 hour before any tests.  Caffeine was dissolved in 10 
oz of a non-caloric, flavored drink while the placebo solution consisted of the drink 
without addition of caffeine.  After 45 minutes of ingestion, subjects were placed in a 




changes on fibrinolysis [58].  At exactly 60 minutes post-ingestion, a pre-exercise blood 
sample (10-ml) was taken.  Blood samples were collected in tubes containing an acidified 
citrate solution (Tcoag Ireland Limited; Bray Co. Wicklow Ireland) for tPA and PAI-1 
activity measurement and in citrate tubes for the analysis of FVIII, tPA Antigen, and 
Fibrinogen.    
Immediately after the blood draw, subjects began a graded exercise test.  All tests 
were performed on a VIAsprint 150P (Sensormedics, California) electronically braked 
cycle ergometer.  The test began at 25 watts and increased 25 watts every minute until 
volitional fatigue or the subject failed to maintain 60 RPMs for more than 5 consecutive 
seconds.  Oxygen uptake and heart rate was measured continuously using a ParvoMedics 
TrueOne Metabolic Cart (Sandy, UT) and at every stage using a Polar Heart Rate 
Monitor (Lake Success, NY), respectively.  VO2peak was defined as the highest 30-
second average obtained during the test. Once the trial was finished, subjects were 
immediately placed in a semi-recumbent position and a post-exercise blood sample (10-
ml) was taken.  All post-exercise samples were obtained within 2 minutes to eliminate 
potential changes in post-exercise fibrinolytic variables [15]. 
 
Genotyping 
Investigators were blinded to genotype until all subjects completed the study. 
Furthermore, all genotyping was performed by an investigator not involved with the 
exercise testing.  DNA was obtained from whole blood samples via an illustra blood 
genomic prep mini spin kit (GE Healthcare Life Sciences.; Buckinghamshire, UK).  Each 




using restriction fragment length polymerase chain reaction (RFLP-PCR), as previously 
described [16].  Subjects were categorized as possessing the C allele (C allele carriers) or 
being homozygous for the A allele (AA homozygotes).  
 
Assays 
Blood samples were centrifuged at 4000 g/min at 4 ˚C for 20 min to obtain 
platelet-poor plasma. Plasma samples were analyzed using an enzyme-linked 
immunosorbancy assay (ELISA) for Factor VIII (Affinity Biologicals; Ontario, CA), 
Tissue Plasminogen Activator (tPA) (Eagle; Nashua,NH), Tissue Plasminogen Antigen 
(Eagle; Nashua, NH), Plasminogen Activator Inhibitor -1 (PA-1)(Molecular Innovations; 
Novi, MI).  Researchers at Ball State University performed analysis of fibrinogen via the 
use of a coagulometer.  
 
Statistical Analysis 
All statistical analysis were conducted using SPSS software (Chicago, IL). A 
three-factor Repeated Measures analysis of variance (RMANOVA) test was ran with 
treatment (caffeine, placebo) and time (pre-exercise, post-exercise) as within-subjects 
factors and genotype (AA homozygotes, C allele carriers) as a between-subjects factor.  
Potential differences in time to fatigue and VO2peak were analyzed using a RMANOVA 
with treatment as the within-subjects factor and genotype as the between-subjects factor.  
For all RMANOVA tests, post-hoc interactions were performed using paired and 







There has been conflicting research related to caffeine’s effect on cardiovascular 
disease, serum lipids, and acute coronary events [6,12,16,29,33,34,44,45,48,53].  Current 
literature shows both J and U-shaped relationships between cardiovascular disease risk 
and coffee consumption, suggesting a type of protective effect for moderate but not light 
or heavy drinkers [29,36,48] .  Furthermore, numerous studies evaluating the 
consumption of caffeinated versus decaffeinated coffee show preventative cardiovascular 
benefits regardless of type [13,34,41] while others show an increased relative risk for 
acute coronary events like myocardial infarction and stroke [29,48,53].  It has also been 
suggested that coffee consumption may acutely trigger a myocardial infarct in sedentary 
individuals that drink less than 2 cups of coffee per day or those not consuming coffee 
daily [6].   
 While the literature in regards to coffee consumption and cardiovascular risk 
remains ambiguous at best, the effect of caffeine on hemodynamic response is 
unequivocal.  Caffeine increases heart rate, blood pressure, myocardial contractility, and 
cardiac output [7,12,13,29,33,34,44,45,49].  Prior data shows that contractility  increases 
90 minutes after ingestion, and does not return to baseline until 4.5 hours after the initial 
dosage [7].  Caffeine’s effect on heart rate is a direct response to increased catecholamine 
release that results in an effect similar to that of other stimulants [12,19,29,33,34,44,45].  




increased neuroendocrine stimulation [12,29,33,34,43-45]. These effects can be seen 
within 30 minutes of consumption and continue for 4 or more hours [43].   
Although hemodynamic responses to caffeine may lead to acute myocardial 
infarction, it is understood that a majority of myocardial infarctions result from an 
occlusive thrombus [24,37,53]. Unstable plaques rupture, resulting in thrombus formation 
that can completely occlude coronary arteries.  Thus, plasma markers of coagulation 
potential and clot lysis (fibrinolysis) are clinically important [50,59].  Markers of 
coagulation potential include factors that make up the coagulation cascade and 
fibrinogen, the inactive precursor to fibrin.  In humans, fibrinolysis is regulated by 
conversion of plasminogen in to plasmin which degrades fibrin to smaller fibrin dimer 
proteins.  The hemostatic response to exercise is of particular clinical significance as 80% 
of exertion-related ischemic events occur due to an occlusive thrombus [24].  Exercise 
acutely increases coagulation potential [20, 21], which is offset by a corresponding 
increase in fibrinolytic activity [59]. 
The equivocal findings on the relationship between coffee intake and risk of MI, 
and the conflicting findings regarding caffeine's effect on hemostasis could be explained 
by genetic differences. Cytochrome P450 (CYP1A2) is a hepatic enzyme that is 
responsible for the metabolism of caffeine.  Cornelius et al observed that a single-
nucleotide (A/C) polymorphism at intron 1 of the CYP1A2 gene influenced the degree to 
which coffee consumption was associated with risk of myocardial infarction [17]. Coffee 
consumption increased MI risk in study participants that possessed a C allele, but was not 
linked to MI risk in individuals homozygous for the A allele.  Prior research has shown 




suggesting that the increased MI risk in C-allele carriers was due to higher plasma 
caffeine levels following caffeine dosage.  This polymorphism has also been shown to 
influence the association between caffeine and bone mineral density [27] and the 
ergogenic response to caffeine in cyclists [60].  The former study evaluated whether the 
CYP1A2 polymorphism impacted the long-term effect of drinking high amounts of 
coffee and corresponding bone mass in an elderly population. Womack et al observed 
that caffeine significantly improved cycling time trial performance in AA homozygotes 
to a greater degree than in C allele carriers [60].  While the mechanisms for these effects 
are still unknown, the implications of such findings suggest that this genetic 
polymorphism exerts a very powerful influence on caffeine response. 
If caffeine increases risk of MI due to alterations in hemostasis, it could be 
hypothesized that the aforementioned CYP1A2 polymorphism would influence the effect 
of caffeine on the coagulation and/or fibrinolytic profile.  The purposes of the present 
study were to:  1) determine the acute effects of caffeine on coagulation and fibrinolytic 
potential at rest and following maximal exercise and 2) determine if hemostatic responses 
engendered by caffeine are influenced by the aforementioned CYP1A2 polymorphism.  It 
is hypothesized that caffeine will increase coagulation potential both at rest and after 











  A total of 20 healthy, recreationally active, males (age, 21.4 ± 1.2 ; weight, 81.9 ± 
10.4 ; 180.6 ± 7.1 ; VO2peak 46.4 ± 6.17  mL∙kg∙min
-1
) participated in this study.  All 
subjects were non-smokers and were recruited from a university setting without any 
reported chronic illness or condition.  Written informed consent was obtained from all 
participants prior to participation.  The study and consent form were approved by the 
James Madison University Institutional Review Board. 
 
Experimental Protocol 
The study used a randomized, double-blind, crossover design.  All subjects 
performed a 10 hour fast on the night before each trial and refrained from the 
consumption of caffeine and alcohol for 24 hours prior to each trial.  Exclusion criteria 
included any illness 7 days prior to the trial as well as the use of medication within 24 
hours of any trial.  Subjects performed two graded maximal exercise tests (GXT’s).  All 
trials were performed before 10:00AM in order to minimize the possibility of diurnal 
variation in fibrinolysis [2].  Subjects ingested 6 mg/kg of pharmaceutical grade caffeine 
(Nutrabio, New Jersey) or placebo 1 hour before any tests.  Caffeine was dissolved in 10 
oz of a non-caloric, flavored drink while the placebo solution consisted of the drink 
without addition of caffeine.  After 45 minutes of ingestion, subjects were placed in a 
semi-recumbent position and rested for 15 minutes to minimize the effect of postural 




sample (10-ml) was taken.  Blood samples were collected in tubes containing an acidified 
citrate solution (Tcoag Ireland Limited; Bray Co. Wicklow Ireland) for tPA and PAI-1 
activity measurement and in regular citrate tubes for the analysis of FVIII, tPA Antigen, 
and Fibrinogen.    
Immediately after the blood draw, subjects began a graded exercise test.  All tests 
were performed on a VIAsprint 150P (Sensormedics, California) electronically braked 
cycle ergometer.    The test began at 25 watts and increased 25 watts every minute until 
volitional fatigue or the subject failed to maintain 60 RPMs for more than 5 consecutive 
seconds.  Oxygen uptake and heart rate was measured continuously using a ParvoMedics 
TrueOne Metabolic Cart (Sandy, UT) and at every stage using a Polar Heart Rate 
Monitor (Lake Success, NY), respectively.  VO2peak was defined as the highest 30-second 
average obtained during the test.  Once the trial was finished, subjects were immediately 
placed in a semi-recumbent position and a post-exercise blood sample (10-ml) was taken.  
All post-exercise samples were obtained within 2 minutes to eliminate potential changes 
in post-exercise fibrinolytic variables [15]. 
 
Genotyping 
Investigators were blinded to genotype until all subjects completed the study. 
Furthermore, all genotyping was performed by an investigator not involved with the 
exercise testing. DNA was obtained from whole blood samples via an Illustra blood 
genomic prep mini spin kit (GE Healthcare Life Sciences.; Buckinghamshire, UK). Each 
blood sample was obtained prior to one of the cycling trials. Genotyping was performed 




described [16].  Subjects were categorized as possessing the C allele (C allele carriers) or 
being homozygous for the A allele (AA homozygotes).  
 
Assays 
Blood samples were centrifuged at 4000 g/min at 4 ˚C for 20 min to obtain 
platelet-poor plasma. Plasma samples were analyzed using an enzyme-linked 
immunosorbancy assay (ELISA) for Factor VIII (Affinity Biologicals; Ontario, CA), 
Tissue Plasminogen Activator (tPA) (Eagle; Nashua,NH), Tissue Plasminogen Antigen 
(Eagle; Nashua, NH), Plasminogen Activator Inhibitor -1 (PA-1)(Molecular Innovations; 
Novi, MI).  Researchers at Ball State University performed analysis of fibrinogen via the 
use of a coagulometer.  
 
Statistical Analysis 
All statistical analysis were conducted using SPSS software (Chicago, IL). A three-factor 
Repeated Measures analysis of variance (RMANOVA) test was performed with treatment 
(caffeine, placebo) and time (pre-exercise, post-exercise) as within-subjects factors and 
genotype (AA homozygotes, C allele carriers) as a between-subjects factor.  Potential 
differences in time to fatigue and VO2peak were analyzed using a RMANOVA with 
treatment as the within-subjects factor and genotype as the between-subjects factor.  For 
all RMANOVA tests, post-hoc interactions were performed using paired and unpaired t-
tests. A P-value < 0.05 was considered statistically significant.  All variables are 





 Of the 20 subjects, 10 (50%) were homozygous for the A allele and 10 (50%) were C 
allele carriers.  This distribution is similar to previously reported studies regarding the presence 
of the polymorphism in a sample population [16,17,60].  Descriptive statistics between the two 
genetic groups are displayed in Table 1.   No significant differences were observed between AA 
homozygotes and C allele carriers for age, weight, height, or VO2peak. There was a trend (p = 
0.09) for increased time to fatigue in the caffeinated (711 ± 139 sec) versus the placebo (687 ± 
112 sec) conditions.   
 Table 2 shows pre and post-exercise values for markers of coagulation potential.  There 
were significant main effects for both treatment (Caffeine > Placebo, p < 0.05) and time (Post-
Exercise > Pre-Exercise, p < 0.05) for plasma levels of Factor VIII (Table 2A).  Factor VIII 
increased by 189% during exercise in the caffeinated condition as compared to 131% during 
exercise in the placebo condition, although there was not a significant treatment x time 
interaction (p = 0.10).  Because of the trend for increased TTF in the caffeine trial, all ANOVA 
analyses were repeated while covarying for the difference in TTF during the caffeine trial and 
TTF in the placebo trial (delta TTF).  As a result of this post-hoc analysis, there was no longer a 
significant effect of treatment on plasma Factor VIII.   None of the other findings were altered.  
Plasma fibrinogen values are shown inTable 2B.  A significant treatment x time x genotype 
interaction was observed due to a  23% increase (p < 0.05) during exercise in the caffeinated 
condition for the C allele carriers.  No significant increase in fibrinogen was observed during 
exercise in the caffeinated condition for the AA homozygotes and no increases were observed for 




Values for fibrinolytic variables are displayed in Table 3.  There were significant main 
effects for both treatment (Caffeine > Placebo, p < 0.05) and time (Post-Exercise > Pre-Exercise, 
p < 0.05) for plasma tPA activity (Table 3A).  There was also a significant treatment x time 
interaction (p < 0.05) due to a larger increase in plasma tPA during exercise in the caffeinated 
condition.  Additionally, a significant time x genotype interaction (p < 0.05) was observed as C 
allele carriers exhibited higher tPA activity post-exercise independent of treatment.  A significant 
main effect of time (Post-Exercise > Pre-Exercise, p < 0.05) was observed for tPA antigen (Table 
3B) although no significant effects of treatment, genotype, or any interaction effects were 














Table 1. Descriptive Characteristics 
 AA (n=10) C (n=10) Total (n=20) 
Age 21.1 ± 1.2 21.7 ± 1.3 21.4 ± 1.27 
Weight (kg) 81.3 ± 9.4 82.6 ± 11.7 81.9 ± 10.4 













Table 2: Markers of Coagulation Potential 
A. Plasma Factor VIII before and after exercise in both treatments for both genetic groups. 
*- Main effect for Treatment (Caffeine > Placebo, p < 0.05); †- Main effect for Time (Post-
Exercise > Pre-Exercise, p < 0.05) 
B. Plasma Fibrinogen before and after exercise in both treatments for both genetic groups. 
**-Significantly greater than pre-exercise (p < 0.05) 
 
Treatment/Group Pre-Exercise Post-Exercise† 
Caffeine*   
AA 1.034 ± .461 2.642 ± 1.50 
C 0.822 ± .442 2.691 ± .933 
Placebo   
AA 1.06 ± .434 2.057 ± 1.14 
C 0.83 ± .335 2.228 ± 1.03 
Treatment/Group Pre-Exercise Post-Exercise 
Caffeine   
AA 343.07 + 163.1 345.87 + 130.7 
C 305.56 + 73.4 376.2  + 126.3** 
Placebo   
AA 330.53  + 172.7 400.0 + 158.2 




Table 3: Markers of Fibrinolytic Potential 
A.  Plasma Tissue Plasminogen Activator (tPA) activity before and after exercise in both 
treatments for both genetic groups. 
*-  Main effect for Treatment (Caffeine > Placebo, p < 0.05); †- Main effect for Time (Post-
Exercise > Pre-Exercise, p < 0.05); ♯-Significant treatment x time interaction, with the 
caffeinated condition exhibiting a higher exercise response (p < 0.05); 
a
-Significant time x 










Caffeine*          ♯ 
AA 0.342 + 0.2 8.234 + 4.3 
C
 a
 0.428 + 0.3 11.285 + 3.2 
Placebo   
AA 0.263 + 0.2 5.391 + 3.0 




B.  Plasma tPA antigen before and after exercise in both treatments for both genetic groups. 
†- Main effect for time (Post-Exercise > Pre-Exercise, p < 0.05) 
C.  Plasma Plasminogen Activator Inhibitor- 1 (PAI-1) before and after exercise in both 





Treatment/Group Pre-Exercise Post-Exercise† 
Caffeine   
AA 1.124 + 1.3 2.552 + 3.3 
C 4.026 + 5.8 6.442 + 8.1 
Placebo   
AA 1.038 + 1.2 2.289 + 3.1 
C 3.987 + 5.8 5.812 + 7.4 
Treatment/Group Pre-Exercise Post-Exercise 
Caffeine   
AA 9.031 + 11.0 8.398 + 9.5 
C 4.774 + 3.5 4.821 + 5.7 
Placebo   
AA 7.578 + 10.8 7.378 + 10.3 





In the present study, we observed an increase in plasma Factor VIII following caffeine 
ingestion.  The process of blood clot formation, or thrombosis, is preceded by several endothelial 
and luminary processes which can be enhanced by the increased presence of plasma clotting 
factors [1,38,46,50,59].  Factor VIII is a part of the intrinsic pathway of the coagulation cascade, 
the main pathway activated during exercise-induced stimulation of coagulation, and prior studies 
have consistently observed increases in this marker in response to exercise [50].  There was a 
main effect for Factor VIII levels post-exercise (p < 0.05) which is consistent with the current 
body of literature regarding post-exercise coagulation potential [50,59].  Thus, the observed 
increases in Factor VIII may have clinical significance given the fact that thrombosis is 
responsible for the majority of exertion related ischemic events [24].  It should also be noted that 
the effect of caffeine on Factor VIII response appeared to be more pronounced post-exercise, 
although there was no significant for a treatment x time interaction (P = 0.10).  Caffeine has been 
linked with ischemic events [6,44,53] and the additional increase in Factor VIII from caffeine in 
combination with strenuous physical activity implies a potential mechanism for this relationship. 
These findings were not found to be mediated by genotype. 
 There was a trend (p = 0.09) for increased Time to Fatigue (TTF) in the caffeinated trials. 
Interestingly, it appears that time to fatigue also influenced the increased Factor VIII response in 
the caffeinated subjects.  The TTF difference between the caffeinated and placebo trials was 
significantly correlated (R = 0.49, p = 0.03) with the magnitude of increase in Factor VIII levels 
when subjects ingested the caffeine supplement.  Repeating the RMANOVA while covarying for 
TTF eliminated the observed main effect of treatment on Factor VIII.  This suggests that 




effect. Because of this particular finding, it is possible that caffeine’s link to ischemic events 
could be due to the physiological response it engenders by its ergogenic effects in lieu of its role 
in clotting potential. 
 Although the CYP1A2 polymorphism did not influence the Factor VIII response to 
caffeine,  C allele carriers exhibited a greater plasma fibrinogen response after ingesting caffeine 
compared to AA homozygotes.  Carriers of the C allele exhibited a 23% increase in post-exercise 
fibrinogen values after ingesting caffeine, whereas the AA homozygotes showed an increase of 
less than 0.1%.  This difference was apparent even after co-varying for delta TTF, suggesting 
that the increased time to fatigue engendered by the caffeine did not influence this response.  
Prior studies on the fibrinogen response to exercise have been equivocal as increases [3], 
decreases [5,51] and static responses [31,52,56] have been observed [8,52].  Furthermore, prior 
studies have observed an association between coffee consumption and myocardial infarction in C 
allele carriers, but not AA homozygotes [16,17].  It is possible that this observation is at least 
partially linked to an increase in fibrinogen in response to physical stress in the C allele carriers.  
While the present study does not definitively support this contention, it is compelling that this 
was the only hemostatic marker investigated that demonstrated a significant treatment x time x 
genotype interaction. 
During exercise, the increased coagulation potential is accompanied by a corresponding 
increase in fibrinolytic potential [1,11,14,26,28,38,39]. Plasma tPA activity has been implicated 
as a strong predictor for acute myocardial infarction in many studies [46,47].  tPA is a precursor 
for the catalyzing process of plasminogen to plasmin, the active enzyme directly responsible for 
the lysis of fibrin clot.  However, after periods of strenuous exercise, markers of both coagulation 




coagulation have been reported to stay elevated anywhere from 6-10 hours after the cessation of 
exercise while markers of fibrinolytic potential have been reported to return to resting levels in 
as few as 10 minutes [28,39,50].  Regardless of whether the increase in post-exercise Factor VIII 
was influenced by test duration, it was counterbalanced by a greater increase in tPA during the 
caffeinated condition. tPA increased 20-fold after exercise for both caffeine and placebo trials, 
supporting the idea of a counterbalanced activity of coagulation immediately after periods of 
maximal exertion.  However,  a significantly greater rise in post-exercise tPA levels was 
observed with the caffeine treatment (Caffeine = 9.59 IU/µl; Placebo = 6.89 IU/µl, p < 0.05), 
suggesting that the increased coagulation potential after exercise in the caffeinated condition was 
counter-balanced by increases in fibrinolytic potential.  In contrast to Factor VIII, however, the 
treatment and treatment x time effect for caffeine remained significant when covarying for the 
difference in time to fatigue.  Some studies have suggested a potential protective effect for CVD 
with caffeine consumption [16,29,45,48,53].  As the present study showed an increase in tPA 
with caffeine consumption, both at rest and in response to stress, it is possible that these 
aforementioned effects are at least partially due to improvements in fibrinolytic potential.  The 
main circulating inhibitor of tPA, PAI-1 was not significantly affected by either caffeine or 
exercise.  While PAI-1 is known to decrease as a response to exercise [15], an absence of any 
response has also been observed [9].  Thus, in the present study, the impact of caffeine on 
fibrinolysis appeared to be confined to increases in tPA activity. 
The CYP1A2 polymorphism did not affect VO2peak or TTF in the current study.  In 
contrast, a study from our lab showed that caffeine supplementation had a more pronounced 
ergogenic effect on 40 km time trial performance in trained cyclists homozygous for the A allele 




participants were not trained cyclists.  It could be that the lack of genetic effect is specific to the 
protocol and/or sample group used in the present study. 
While the findings from the present study suggest a hemostatic response from caffeine 
and a genetic influence on this hemostatic response, there are some caveats that should be noted. 
Our study of healthy, college-aged males did not include analysis of any clinical population and 
so our results cannot be extended to populations that may have increased coagulation potential 
and/or decreased fibrinolysis.  In addition, it has been proposed that hormonal fluctuations 
during the menstrual cycle may affect coagulation and fibrinolysis, at least acutely, and so our 
results may not be accurately translated to females.  Also, there was no post-exercise period of 
measurements taken from subjects other than those upon immediate cessation of the maximal 
exercise test.  Thus, it is not known the degree to which caffeine affected these markers in the 
post-exercise period and to what extent the studied polymorphism influenced any effect.  The 
area of research regarding caffeine’s relationship to ischemic events is extremely limited as the 
majority of literature is in regards to coffee and cardiovascular disease risk.  It is because of this 
that our results may not be indicative of the effect that coffee has on coagulation potential.  
Lastly, the subject number used in this study is substantially less than that of what is typically 
used in studies regarding polymorphisms and genetic differences.  Thus it is possible that not 
enough participants were observed to detect some of the potential genetic differences.  However, 
no trends were evident for either genotype x treatment or genotype x treatment x time 
interactions for any of the variables examined in the present study.  In summary, the present 
study suggests that caffeine increases resting and post-exercise tPA activity levels.  Furthermore, 
caffeine may increase Factor VIII response to graded exercise secondary to an effect on time to 




response to exercise; as only C allele carriers exhibited a significant increase in fibrinogen during 
exercise in the caffeinated condition.    Future research should evaluate the link between this 
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